Loading doctor profile...
Hematologist, specializing in Hematologic Cancers
Dr. Michael J. Mauro, MD, is a nationally recognized hematologist-oncologist specializing in chronic myeloid leukemia (CML) and other myeloproliferative neoplasms. He serves as Director of the Myeloproliferative Neoplasms Program within the Leukemia Service at Memorial Sloan Kettering Cancer Center, where he leads clinical and translational efforts to improve outcomes in chronic blood cancers. Dr. Mauro earned his medical degree from Dartmouth Medical School and completed his residency and fellowship training at NewYork-Presbyterian/Weill Cornell Medical Center. Prior to joining Memorial Sloan Kettering, he spent over a decade at the Oregon Health & Science University Knight Cancer Institute, where he played a key role in developing early clinical trials for tyrosine kinase inhibitors, including imatinib.
Dr. Mauro is widely known for his expertise in managing CML, myelofibrosis, polycythemia vera, and other chronic myeloid disorders. His clinical focus includes therapeutic optimization, resistance management, side effect mitigation, and long-term treatment-free remission. He has authored numerous peer-reviewed publications and clinical commentaries, and his research continues to influence the evolving standard of care for patients with myeloproliferative neoplasms. In addition to his clinical practice, he remains active in national working groups and research consortia dedicated to the advancement of molecular-targeted therapies in hematologic malignancies.
Beyond his research and clinical leadership, Dr. Mauro is a committed educator and mentor, guiding fellows and junior faculty in the field of hematologic oncology. Board-certified in internal medicine, hematology, and medical oncology, he is known for his analytical approach to complex disease management and his deep commitment to patient-centered care. Through his continued leadership in translational research, targeted therapy development, and academic mentorship, Dr. Mauro remains at the forefront of innovation in the treatment of chronic myeloid disorders.
Health insurance plans can change over time. If your plan isn't listed below, it may still be accepted by this doctor. Always contact the doctor's office to confirm your coverage.
